Patients with primary elevations of low-density lipoprotein cholesterol (LDL-C) ≥190 mg/dL are at a higher risk of atherosclerotic cardiovascular disease as a result of long-term exposure to markedly elevated LDL-C levels. Therefore, initiation of statin therapy is recommended for these individuals. However, there is a lack of randomized trial evidence supporting these recommendations in primary prevention. In the present analysis, we provide hitherto unpublished data on the cardiovascular effects of LDL-C lowering among a primary prevention population with LDL-C ≥190 mg/dL.
ORIGINAL RESEARCH ARTICLE P atients with primary elevations of low-density lipoprotein cholesterol (LDL-C) ≥190 mg/dL (to convert values for cholesterol to mmol/L, multiply by 0.02586) are at a higher risk of atherosclerotic cardiovascular disease (ASCVD) as a result of a longterm exposure to markedly elevated LDL-C levels, even in the absence of preexisting ASCVD (ie, primary prevention). 1, 2 This recently has been further supported by observations from the Cardiovascular Lifetime Risk Pooling Project, where these individuals, who were even referred to as familial hypercholesterolemia (FH) phenotype ( Table I in the online-only Data Supplement), were observed to have an accelerated risk of coronary heart disease (CHD) and ASCVD in comparison with individuals with average levels of LDL-C. 3 As such, the initiation of statin therapy (and, more recently, also of PCSK9 [proprotein convertase subtilisin/kexin type 9] inhibitors to further reduce LDL-C levels) is recommended for individuals with primary elevations of LDL-C ≥190 mg/dL without the need for risk assessment. 1, 2, 4 However, there is a lack of published randomized trial evidence supporting these recommendations in primary prevention with available evidence extrapolated from the Cholesterol Treatment Trialist meta-analyses (where lower LDL-C cutoff points were used and patients with established vascular disease were included in the high LDL-C category). 5, 6 Currently, it would be unethical to perform a placebo-controlled trial of LDL-C-lowering therapy among individuals with LDL-C ≥190 mg/dL. Nonetheless, we can address this question using data from WOSCOPS (West Of Scotland Coronary Prevention Study), which aimed to assess the benefits of statin therapy among men with hypercholesterolemia and enrolled a significant proportion of patients with LDL-C ≥190 mg/dL (mean LDL-C 192 mg/dL). 7, 8 Although WOSCOPS excluded individuals with apparent myocardial infarction (MI), a proportion of participants still had evidence of other vascular diseases at baseline.
In the present analysis, we provide hitherto unpublished data on the cardiovascular effects of LDL-C lowering among a population with primary elevation of LDL-C ≥190 mg/dL after restricting analyses to participants without evidence of vascular disease at baseline. Furthermore, clinical guidelines have differed on whether to recommend percentage reductions in LDL-C or specific LDL-C levels among such patients. 1, 9, 10 To provide practical insights into desirable reductions in LDL-C among these individuals, we also conducted an observational analysis that assessed the relationship between reductions in LDL-C (in relative or absolute terms) and on-treatment LDL-C levels with subsequent clinical events.
METHODS

Randomized Trial
Details of the design of WOSCOPS have been described in detail elsewhere. 7, 8 In brief, WOSCOPS enrolled 6595 men aged 45 to 64 years (mean age 55 years) without evidence of prior MI and with a LDL-C ≥155 mg/dL not receiving lipidlowering therapy (mean LDL-C 192 mg/dL). Patients likely to have an elevated LDL-C attributable to secondary causes or with LDL-C >232 mg/dL on 2 fasting lipid measurements during the screening phase were excluded (Methods and Figure I in the online-only Data Supplement). Subjects were then randomly assigned (double-blind) to pravastatin 40 mg once daily or placebo. Mean follow-up was 4.9 years (range, 3.1-6.1).
To assess a purely primary prevention population, the present analyses adopted more rigorous criteria than those used in the main WOSCOPS trial and, in addition, excluded those individuals with any evidence of vascular disease at baseline (n=1066) namely, evidence of angina, intermittent claudication, stroke, transient ischemic attack, and minor ECG abnormalities (classified by Minnesota code). 7, 8, 11 Patients were then stratified by LDL-C levels at baseline into those with LDL-C <190 mg/dL and those with LDL-C ≥190 mg/dL ( Figure I and 
Clinical Perspective
What Is New?
• The present analysis from the WOSCOPS trial (West of Scotland Coronary Prevention Study) reports for the first time new information on >2500 men with low-density lipoprotein cholesterol (LDL-C) ≥190 mg/dL without preexisting vascular disease (a group lacking randomized trial evidence for statin therapy) and their subsequent risk of cardiovascular events. • Individuals with a LDL-C ≥190 mg/dL have a 2-fold higher observed risk of major cardiovascular events than would be predicted from a risk calculator. • We provide compelling novel evidence from a randomized trial supporting the benefit of LDL-C lowering on cardiovascular events among a primary prevention population with LDL-C ≥190 mg/dL.
What Are the Clinical Implications?
• The present analysis provides novel supporting evidence from a randomized trial to reinforce current recommendations of initiation of lipid-lowering therapy in the primary prevention of individuals with primary elevations of LDL-C ≥190 mg/dL without the need for risk estimation. • Although these analyses are post hoc, this approach is the only one that currently allows us to address this question, because (1) nowadays it would be unethical to perform a placebo-controlled trial in the population with LDL-C ≥190 mg/dL, and (2) there is no other randomized trial in primary prevention with statins including such a significant proportion of patients with an LDL-C ≥190 mg/dL. Table I in the online-only Data Supplement). The following principal end points were considered for the present analysis to maximize power (given the smaller sample size resulting from the stricter exclusion criteria and further restricting analysis to approximately half of the remaining individuals, ie, participants with LDL-C ≥190 mg/dL): (1) the composite of definite or suspected nonfatal MI plus definite or suspected CHD death, hereinafter referred to as CHD (same coprincipal end point as the original WOSCOPS trial); (2) the composite of cardiovascular death, nonfatal MI (definite or suspected), and nonfatal stroke (major adverse cardiovascular events [MACE] ). End point definitions including definite and suspected coronary events are shown in the Methods in the online-only Data Supplement. Other outcomes explored include the principal end points but restricted to definite-only coronary events, MACE including coronary revascularization, mortality end points (CHD death, cardiovascular death, and all-cause mortality), coronary revascularization, and cerebrovascular events (fatal/nonfatal stroke and transient ischemic attack).
Extended Observational Long-Term Follow-Up
After completion of the randomized trial phase, an extended observational follow-up of the WOSCOPS cohort is now ongoing, through linkage to national mortality and electronic hospital discharge records held by the National Health Service for Scotland. 12, 13 Further details are available in the Methods in the online-only Data Supplement, but, in brief, at 5 years after the initial trial finished approximately one-third of individuals originally allocated to pravastatin or placebo were on statins. In the present analysis, we compared long-term mortality outcomes (including deaths from CHD, cardiovascular causes, and any cause) between those originally randomly assigned to pravastatin in comparison with placebo among individuals without evidence of vascular disease at baseline stratified by hypercholesterolemia status.
Ethics
The ethics committees from the University of Glasgow and participating health boards in Scotland approved the original WOSCOPS trial. The corresponding committees from the Glasgow Royal Infirmary and Privacy Advisory Committee of the National Health Service for Scotland approved the extended follow-up study. The participants in each phase of WOSCOPS provided informed consent to partake in the trial and review of their medical records.
Statistical Analysis
Effect of Statin Therapy on Outcomes
The effect of therapy (pravastatin versus placebo) among those with and without LDL-C ≥190 mg/dL was calculated for both the initial trial period and the extended follow-up. Estimates of hazard ratios and 95% confidence intervals with corresponding P values were obtained by means of a Cox proportional hazards model with randomized therapy as the only covariate. A test for interaction was performed to assess whether the effect of therapy was consistent across the LDL-C strata prespecified for this analysis. The P value obtained from the treatment by LDL-C subgroup interaction term was reported. Time-to-event curves were estimated by using the Kaplan-Meier method based on the original treatment arm and LDL-C strata. Tests were 2-sided and statistical significance was defined as P<0.05.
Changes in LDL-C and Outcomes
To elucidate the extent to which the magnitude of LDL-C reduction from pravastatin therapy influenced outcomes among those with LDL-C ≥190 mg/dL, observational analyses were performed. Therefore, we assessed changes in LDL-C levels and pravastatin effect during the randomized trial restricted to those subjects with LDL-C ≥190 mg/dL at baseline. The placebo group was taken as the reference category for the models. The relationship between absolute LDL-C fall (mean baseline level minus mean on-treatment value) or percentage LDL-C reduction and risk of events were assessed by using multivariable Cox regression models (Wald test) for the different groups (placebo and pravastatin subgroups), accounting for the following covariates: age, smoking, blood pressure, history of hypertension, diabetes mellitus, and body mass index, as previously published. 5, 14 LDL-C reductions were modeled as categorical variables based on previous WOSCOPS and Cholesterol Treatment Trialist publications. 5, 6, 14 For the assessment of the relative fall in LDL-C, >30% and <30% was used (consistent with the perceived average potency of pravastatin 40 mg/d: moderate-intensity statin therapy). 1
On-Treatment LDL-C and Outcomes
The relationship between on-treatment LDL-C levels achieved with therapy on the risk of events was studied following analyses similar to those described above. Consistent with previous WOSCOPS analyses, 14 on-treatment lipid levels were defined as the mean of all lipid values measured after randomization until the patient had an event or reached the end of the trial. On-treatment LDL-C analyses excluded individuals with events in the first 6 months of the trial, because first on-treatment lipid measurements were at 6 months after randomization.
Participants With a Predicted 10-Year ASCVD Risk <7.5% and No Diabetes Mellitus
Finally, we performed additional analyses among participants without an indication of statin therapy based on global cardiovascular risk estimation and who were free from diabetes mellitus in whom LDL-C was ≥190 mg/dL (and for comparison <190 mg/dL), to specifically assess the impact of LDL-C-related cardiovascular risk. To assess global cardiovascular risk, we applied the Pooled Cohort Risk Equations 15 to the members of the WOSCOPS cohort who were free from ASCVD and diabetes mellitus, restricted to those with a predicted 10-year ASCVD risk <7.5%. To maximize power, we focused on MACE during the 5-year on-trial period and 20-year extended follow-up. The statistical analyses were performed using SAS v9.2 (SAS Institute Inc). ORIGINAL RESEARCH ARTICLE these, 2560 individuals had LDL-C ≥190 mg/dL (placebo n=1274; pravastatin n=1286). The baseline characteristics, stratified by the presence or absence of LDL-C ≥190 mg/dL, comparing pravastatin with placebo treatment groups are shown in Table 1 . Overall, patients had a mean age of 55 years, and there were no significant differences between placebo-and pravastatin-treated groups in any of the characteristics.
Lipid Levels
LDL-C levels at baseline, 1 year, and end of trial, and the percentage changes from baseline to year 1 and to end of trial, as well, are shown in Table 1 . Mean (±SD) LDL-C at baseline was 206±12 mg/dL among patients with LDL-C ≥190 mg/dL, and 178±6 mg/dL among those with LDL-C <190 mg/dL. LDL-C levels at year 1 and end of trial were significantly lower among pravastatin-treated subjects in comparison with placebo across cohorts (P<0.001). The percentage reduction in LDL-C from baseline with pravastatin (accounting for the effect of placebo) among those with and without LDL-C ≥190 mg/dL was of a similar magnitude (≈23% at year 1 and 19.5%-20% at end of trial) ( Figure II in the online-only Data Supplement). The effects on other lipids are shown in Table II in the online-only Data Supplement.
Initial Trial Phase
The effect of pravastatin versus placebo on cardiovascular outcomes over 4.9 years stratified by LDL-C <190 or ≥190 mg/dL is shown in Figure 1 , Table 2 , and Table  III in the online-only Data Supplement. Overall, both CHD and MACE were reduced in the 5529 patients without vascular disease. Analyses stratified by LDL-C status showed no evidence of heterogeneity between cohorts for the principal end points or for the additional outcomes explored (interaction P values all >0.2) (interaction results did not materially change when using LDL-C as a continuous measure rather than categorical [ Table IV in the online-only Data Supplement]). The cor- Data are shown as absolute and relative (%) number of subjects for categorical variables and as mean±SD or median (interquartile range) for continuous parameters. To convert values for cholesterol to mmol/L, multiply by 0.02586. To convert values for triglycerides to mmol/L, multiply by 0.01129. BP indicates blood pressure; HDL-C, high-density lipoprotein cholesterol; and LDL-C, low-density lipoprotein cholesterol. Figure 1 . End points during the randomized trial period, overall, and stratified by LDL-C levels at baseline. Effect of therapy (versus placebo) shown as hazard ratio (HR) and corresponding 95% confidence interval (95% CI). *Including coronary events (ie, nonfatal myocardial infarction and CHD death) as definite only. To convert values for cholesterol to mmol/L, multiply by 0.02586. CHD indicates coronary heart disease; LDL-C, low-density lipoprotein cholesterol; MACE, major adverse cardiovascular events, defined as the composite of cardiovascular death, nonfatal myocardial infarction, and nonfatal stroke; and TIA, transient ischemic attack. 
Long-Term Follow-Up
The effect of initial randomization to pravastatin or placebo on mortality end points during a total of 20 years of follow-up (from randomization to the end of extended follow-up) is shown in Figure 4 and Figures VI through VIII in the online-only Data Supplement. Overall, among all subjects initially allocated to pravastatin, CHD death, cardiovascular death, and all-cause mortality were significantly reduced by 22%, 17%, and 12%, respectively ( Table 2 ). Long-term risk of CHD death, cardiovascular death, and all-cause mortality were significantly reduced by 28%, 25%, and 18%, respectively, among those with LDL-C ≥190 mg/dL originally randomly assigned to pravastatin. The absolute reduction in the risk of death at 20 years from CHD, cardiovascular causes, and any cause was at least 2-fold greater among patients with LDL-C ≥190 mg/dL (absolute risk reduction 2.34%, 3.25%, and 5.39%, respectively) in Effect of therapy (versus placebo) shown as hazard ratios (HRs) and corresponding 95% confidence intervals (95% CIs) and P value. Five-year randomized trial: from randomization to end of randomized trial (on-trial period). Twenty-year long-term follow-up: from randomization to the end of extended follow-up (on-trial plus posttrial periods). Results for the 15-year posttrial period only (from end of randomized trial to end of extended follow-up) did not materially differ from those in the 20-year long-term follow-up and are presented in Table V in 
Change in LDL-C and Outcomes
Among individuals with LDL-C ≥190 mg/dL, reduction in LDL-C of >30% or >39 mg/dL (1 mmol/L) was associated with a lower risk of CHD and MACE in comparison with placebo ( Figure 5 , Tables VI and VII in the online-only Data Supplement). In contrast, those individuals allocated to pravastatin whose LDL-C reduction was <30% or <39 mg/dL were not significantly different from placebo. Consistent with earlier publications from WOSCOPS, we did not observe a continuous relationship between lower achieved LDL-C and outcomes ( Figure 5 , Tables VI through VIII in the online-only Data Supplement).
Participants With a Predicted 10-Year ASCVD Risk <7.5% and No Diabetes Mellitus
Using the Pooled Cohort Risk Equations, 15 participants were stratified into those free from diabetes mellitus and with a 10-year predicted risk of MACE at baseline of <7.5% but with a LDL-C ≥190 mg/dL (n=1714), representing 67% of the initial primary prevention cohort with LDL-C ≥190 mg/dL (Table 3) . During the 5-year trial period, MACE was significantly reduced to 4.8% among those allocated to pravastatin in contrast to a rate of 7.5% among placebo, representing a 38% reduction in risk (hazard ratio, 0.62; 95% confidence Five-year follow-up Kaplan-Meier analysis for coronary heart disease (CHD) end point, stratified by LDL-C at baseline (<190 or ≥190 mg/dL) and treatment allocation at randomization (pravastatin or placebo). Number of events in each group were as follows: placebo, LDL-C <190 mg/dL: n=104; pravastatin, LDL-C <190 mg/dL: n=75; placebo, LDL-C ≥190 mg/dL: n=107; pravastatin, LDL-C ≥190 mg/dL: n=80. To convert values for cholesterol to mmol/L, multiply by 0.02586.CI indicates confidence interval; HR, hazard ratio; and LDL-C, low-density lipoprotein cholesterol. ORIGINAL RESEARCH ARTICLE interval, 0.42-0.92; P=0.018). During the 20-year extended follow-up, the corresponding rates were 18.76% versus 24.18%, representing a risk reduction of 27% (hazard ratio, 0.73; 95% confidence interval, 0.60-0.90; P=0.003). There was no evidence of heterogeneity among those with LDL-C <190 mg/dL and a predicted 10-year risk <7.5% treated with pravastatin ( Table 3 and Table IX in the online-only Data Supplement).
DISCUSSION
Observational data support the assertion that having a LDL-C ≥190 mg/dL is associated with increased cardiovascular risk, even in the absence of other risk fac-tors. 3 However, current guidelines recognize the paucity of evidence for primary prevention among these individuals and, specifically, the lack of evidence from randomized trials that include only patients with LDL-C ≥190 mg/dL. 1 Instead, indirect evidence derived from the extrapolation of other data is used to support this viewpoint. 1 Indeed, the largest evidence base is derived from the Cholesterol Treatment Trialist meta-analyses, where a significant reduction in major coronary events and major vascular events per 39 mg/dL reduction in LDL-C with statins was observed across different categories of baseline LDL-C, including those with LDL-C ≥135 mg/dL 5 or with LDL-C >174 mg/dL, 6 but these groups included patients with established vascular disease. Thus, although the primary prevention of cardio-
Figure 3. Major adverse cardiovascular events risk: Kaplan-Meier curves during the randomized trial period stratified by LDL-C levels at baseline and treatment allocation.
Five-year follow-up Kaplan-Meier analysis for MACE end point, stratified by LDL-C levels at baseline (<190 or ≥190 mg/dL) and treatment allocation at randomization (pravastatin or placebo). Number of events in each group were as follows: placebo, LDL-C <190 mg/dL: n=119; pravastatin, LDL-C <190 mg/dL: n=90; placebo, LDL-C ≥190 mg/dL: n=121; pravastatin, LDL-C ≥190 mg/dL: n=93. To convert values for cholesterol to mmol/L, multiply by 0.02586. CI indicates confidence interval; HR, hazard ratio; LDL-C, low-density lipoprotein cholesterol; and MACE, major adverse cardiovascular events, defined as the composite of cardiovascular death, nonfatal myocardial infarction, and nonfatal stroke. vascular disease in adults with primary elevations of LDL-C ≥190 mg/dL is identified as one of the groups where the benefit of statin therapy exceeds the risk of adverse events, the data currently available from randomized clinical trials are still limited. 1, 2 The present analyses from the WOSCOPS study provide, for the first time, evidence from a randomized trial supporting the benefit of LDL-C reduction in the primary prevention of ASCVD in those with LDL-C ≥190 mg/ dL. Specifically, we provide 3 lines of evidence for the benefit of LDL-C lowering with statins in these patients:
(1) randomized trial evidence that LDL-C reduction by approximately one-quarter with statins reduces the risk of CHD by 27% and of MACE by 25%; (2) extended follow-up evidence that the early benefits extend to reductions in CHD death by 28%, cardiovascular death by 25%, and all-cause mortality by 18% over 20 years; the greater absolute benefit and smaller numbers neededto-treat in patients with LDL-C ≥190 mg/dL likely reflect the higher lifetime cardiovascular risk because of the cumulative atherosclerotic burden in comparison with those with LDL-C <190 mg/dL; (3) observational data showing that reductions >30% or >39 mg/dL are associated with lower risk of CHD and MACE in comparison with placebo. Another consideration of our results is that LDL-C does not appear to be an effect modifier of outcomes at either 5 years or at 20 years of follow-up (all interaction P values >0.18); in addition, there is not much difference in event rates based on the LDL-C cutoff of 190 mg/dL during the initial 5-year trial period. While these data provide support for statin therapy for primary prevention in subjects with LDL-C ≥190 mg/ dL, the data also provide support for the use of statin therapy for those with LDL-C <190 mg/dL (lower limit for inclusion being 155 mg/dL).
To assess the importance of LDL-C to cardiovascular risk, we conducted an analysis among the primaryprevention cohort in WOSCOPS who were free of diabetes mellitus at baseline and who, on the basis of the current Pooled Cohort Risk Equations, would be considered at low risk (ie, 10-year predicted risk <7.5%) and otherwise would be ineligible for statin therapy (approximately two-thirds). Among placebo-treated patients with LDL-C ≥190 mg/dL, the observed risk of MACE at 5 years was already 7.5%, ie, double what would have been predicted using a risk calculator. In comparison, among those with a LDL-C between 155 and 190 mg/dL, the 5-year risk of MACE was 5.7% in the placebo group. These data reinforce the notion that among patients with a LDL-C ≥190 mg/dL, the observed risk is much greater than would be predicted through a risk calculator, and, thus, global risk estimation is not necessary. During the 5-year randomized trial period, patients with a LDL-C ≥190 mg/dL but with a 10-year predicted risk <7.5% derived a statistically significant ORIGINAL RESEARCH ARTICLE 2.7% absolute risk reduction in MACE with pravastatin (relative risk reduction 38%).
We studied a primary prevention population with a LDL-C ≥190 mg/dL, also defined by some guidelines as primary severe hypercholesterolemia. 1 Some have also referred to patients with LDL-C ≥190 mg/dL as FH phe-notype 3, 4 (Table I in the online-only Data Supplement). However, FH does not have a gold-standard definition, and its prevalence may ultimately depend on the LDL-C threshold and the presence of a pathogenic gene variant. 4, 16 Notwithstanding this, individuals with LDL-C ≥190 mg/dL are more likely to have FH by clinical and Figure 5 . Principal end points during the randomized trial period based on different categories of LDL-C levels with pravastatin in subjects with LDL-C ≥190 mg/dL at baseline. Effect of therapy (versus placebo) shown as hazard ratio (HR) and corresponding 95% confidence interval (95% CI). Note that the MACE plus coronary revascularization end point was used here instead of MACE alone to increase the number of events in each stratum, and so the power of the analysis in a sample otherwise restricted to those with LDL-C ≥190 mg/dL allocated to pravastatin further stratified in different groups as shown in the table. Hazard ratios are adjusted for age, history of hypertension, history of diabetes mellitus, smoking status, systolic and diastolic blood pressure, and body mass index. On-treatment LDL-C levels are defined as the mean of all LDL-C values measured after randomization until the patient had an event or reached the end of the study. On-treatment LDL-C analyses excluded individuals with events in the first 6 months of the trial, because first on-treatment LDL-C measurement was at 6 months after randomization. To convert values for cholesterol to mmol/L, multiply by 0.02586. CI indicates confidence interval; HR, hazard ratio; LDL-C, low-density lipoprotein cholesterol; and MACE, major adverse cardiovascular events, defined as the composite of cardiovascular death, nonfatal myocardial infarction, and nonfatal stroke. 15 Effect of therapy (versus placebo) shown as hazard ratios (HRs) and corresponding 95% confidence intervals (95% CIs) and P value. Five-year randomized trial: from randomization to end of randomized trial (on-trial period). Twenty-year long-term followup: from randomization to end of extended follow-up (on-trial plus posttrial periods). To convert values for cholesterol to mmol/L, multiply by 0.02586. ASCVD indicates atherosclerotic cardiovascular disease; LDL-C, low-density lipoprotein cholesterol; and MACE, major adverse cardiovascular events, defined as the composite of cardiovascular death, nonfatal myocardial infarction, and nonfatal stroke. Table I in the online-only Data Supplement). 9, [17] [18] [19] However, according to a recent study, only a small proportion of people with severe hypercholesterolemia in the community have an identifiable FH mutation. 16 In the present study, we lacked genetic data and indeed relevant clinical information to help define FH in the WOSCOPS population according to accepted diagnostic criteria 9 ; however, the number of individuals who fulfil the strict clinical or genetic criteria for FH in the present analyses is likely to have been small, because WOSCOPS excluded patients with LDL-C >232 mg/dL or with prior MI. 7 Hence, a number of patients with more severe manifestations of FH (in terms of higher LDL-C levels or coronary disease at an earlier age) might have been excluded. Nevertheless, our results are applicable to the broader FH population, based on (1) that there was no heterogeneity in treatment effect between patients with and without LDL-C ≥190 mg/dL; (2) our observation that individuals with primary elevation of LDL-C ≥190 mg/dL and likely greater lifetime burden from elevated LDL-C derive significant risk reductions from LDL-C lowering; and (3) a number of observational studies that suggest the benefit of statins for FH patients. [20] [21] [22] [23] The American College of Cardiology/American Heart Association cholesterol guidelines recommend highintensity statin therapy for individuals with LDL-C ≥190 mg/dL, 1 and, although the present analyses provide direct evidence for the benefits for an ≈23% reduction in LDL-C (ie, a low-intensity statin regimen), there are no trials presently capable of providing similar evidence for the benefit of even greater percentage reductions or higher intensity statin therapy in this population. Although the current paradigm is that lower on-treatment LDL-C levels and greater reductions in LDL-C are associated with a lower risk of ASCVD, [24] [25] [26] we did not find evidence for a continuous relationship between ontreatment LDL-C and better outcomes, which is consistent with earlier analyses from the overall WOSCOPS cohort. 14 To what degree this reflects studies of pravastatin and its relevance to more contemporary statin use is uncertain. Because the inclusion criterion was an LDL-C of 155 to 232 mg/dL and the average LDL-C reduction at 1 year was ≈ 23%, we did not have the data to validate or refute the current recommendation for a LDL-C target of 100 mg/dL in some guidelines. 9, 10 When LDL-C reductions in the pravastatin group were analyzed as a binary trait, the present analyses suggested that those individuals who derived >30% reduction or >39 mg/dL absolute lowering in LDL-C appeared to derive significant benefit in comparison with placebo. It should be recognized, however, that there was considerable overlap in the observed benefits between this group and those achieving lesser reductions on pravastatin. We also need to acknowledge that a fair number of people in the lower-effect group never took the treatment or withdrew from treatment. We know that 9% of the original WOSCOPS cohort never took the treatment and ≈30% were off treatment by 5 years (no significant difference in the withdrawal rates between pravastatin and placebo arms). 8 Many of these people attended the annual visits and had their lipids assessed because they saw the study doctor and had ECGs recorded. Hence, we cannot say that any trends to differences seen are differences in statin response.
The high baseline LDL-C and the limited potency of pravastatin 40 mg/d limit the extent of the analyses that can be performed in WOSCOPS. Direct evidence for the benefit of even greater reductions in LDL-C among patients with LDL-C ≥190 mg/dL in primary prevention may be inferred indirectly from the recently reported SPIRE-2 trial (Studies of PCSK9 Inhibition and the Reduction of Vascular Events), [27] [28] [29] evaluating the efficacy of PCSK9 inhibition with bococizumab in reducing the risk of major cardiovascular events in subjects with LDL-C ≥100 mg/dL despite maximally tolerated statin therapy. With a mean baseline LDL-C level of 134 mg/ dL, and assuming a 50% reduction in LDL-C from intensive statin therapy, suggests that many participants in the SPIRE-2 trial likely started with untreated LDL-C levels ≥190 mg/dL. Therapy with bococizumab led to a reduction in LDL-C levels of ≈55% and 40% at 14 and 52 weeks, respectively. 29 Although the trial was prematurely stopped because of the development of high rates of antidrug antibodies and attenuation of the cholesterol-lowering effect over time, a significant 21% risk reduction of cardiovascular events was observed in those treated with bococizumab (in comparison with placebo) after a median follow-up of 12 months, with no significant differences in analyses stratified by the presence or absence of clinical evidence of cardiovascular disease. 29 It is noteworthy that the National Lipid Association has recently recommended that therapy with PCSK9 inhibitors may be considered to further reduce LDL-C in patients with LDL-C ≥190 mg/dL. 4 A major strength of the present analysis is that it explores a group of higher-risk individuals (LDL-C ≥190 mg/dL) specifically highlighted in guidelines, but one in which clinical trial evidence is lacking. 1 Thus, the present results from a randomized trial provide novel information and evidence to support guideline recommendations. In addition, because high lipid levels like those included in WOSCOPS (LDL-C ≥155 mg/dL) may be present in a significant proportion of the population, the results of the present study may impact the care of a significant number of patients; for instance, recent surveys from the United States have estimated a prevalence of 16% to 33% for LDL-C ≥155 to 160 mg/dL and of 5.6% to 10.4% for LDL-C ≥190 mg/dL (depending on the characteristics of the population scrutinized) in the adult population. 30, 31 That said, some aspects of the present analyses warrant further discussion. This is an ORIGINAL RESEARCH ARTICLE analysis of a subgroup of the overall WOSCOPS cohort that was not prespecified and, although the findings are consistent with the original trial publications, 8, [12] [13] [14] the present findings remain post hoc. The lack of statistically significant reductions in additional end points in the group with LDL-C ≥190 mg/dL (Figure 1 ) may reflect a limited power resulting from restricting the original sample size. In addition, it should be noted that the LDL-C levels in those with LDL-C <190 mg/dL were still high (mean LDL-C at baseline 178 mg/dL overall; at year 1, 177 and 135 mg/dL in placebo and pravastatin arms, respectively) and not markedly different than in those with LDL-C ≥190 mg/dL (mean LDL-C at baseline 206 mg/dL overall; at year 1, 199 and 157 mg/dL in placebo and pravastatin arms, respectively); as such, the difference in absolute risk reduction between these groups may not have been as wide as could be observed in current populations where mean LDL-C levels (in those with LDL-C <190 mg/dL) are significantly lower.
The extended long-term follow-up reports data among individuals enrolled in the original trial and, although the comparisons provided are for the original randomized groups, it should be recognized that the data from the additional 15 years of follow-up after the original trial was completed are observational and might be confounded by the lack of ongoing information regarding medication use. For instance, those participants with LDL-C ≥190 mg/dL may have been more likely to be kept on treatment than those with lower LDL-C levels after the completion of the trial. Nevertheless, it provides valuable information on what a period of treatment may confer in terms of long-term risk reduction benefit (legacy effect or reset of the atherosclerotic event clock based on the original trial). Nevertheless, without excluding the possibility of confounding factors, it is not possible to fully characterize the long-term follow-up estimates as either underestimates or overestimates, because it cannot be assumed that the outcomes are only modulated by statin use or nonuse. Notwithstanding this, we consider that the former is more likely because (1) many actively treated patients during the trial phase may have no longer received statin therapy, and (2) the expected increased crossover in the original placebo arm to statin therapy during follow-up; as such, the results of the extended follow-up may likely underestimate the benefits of longer-term therapy because of the reduced differential statin use over time, and so it is likely that the benefit for those ≥190 mg/dL may be larger than that implied by the trial (especially if one were to use a statin regimen of greater potency than that used in WOSCOPS). On the other hand, the high prevalence of smokers in the WOSCOPS population might mean that a similar study today might not show as strong an effect with a statin regimen of similar potency.
Regarding the exploratory analyses evaluating the effect of LDL-C change on treatment versus outcome (in comparison with placebo), the influence of noncompliance to medication cannot be ruled out completely. That said, to be included in the analysis, men had to attend to have their blood sample taken; many noncompliers did not do so (which is why the achieved LDL-C rose slightly over time). Thus, there is some allowance for noncompliance in the analysis as performed. Finally, the analyses of reductions in LDL-C on pravastatin and outcomes are observational in nature and should be interpreted as such, because residual confounding cannot be excluded despite statistical adjustment.
CONCLUSION
Among men with primary elevations of LDL-C levels ≥190 mg/dL, primary prevention with pravastatin reduced the risk of cardiovascular events. Thus, the present analyses from a randomized clinical trial provide, for the first time, evidence for the benefits of LDL-C lowering for the primary prevention of cardiovascular disease among individuals with primary elevations of LDL-C ≥190 mg/dL, which may help reinforce current recommendations for this group of patients.
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1.-SUPPLEMENTAL METHODS
Participants (men aged 45 to 64) were screened in primary care facilities in the West of Scotland district (after they were identified from doctor´s age/sex registers and invited by mail to attend non-fasting screening clinics). S1 Fasting lipid levels were measured centrally according to the Lipid Research Clinic's protocol. S1 Those individuals with a total cholesterol level greater than or equal to 251 mg/dL (6.5 mmol/L) were given dietary advice on cholesterol reduction and invited to return in 4 weeks. S1 A complete lipoprotein analysis, including low-density lipoprotein cholesterol (LDL-C) levels, were then measured (14 hr fasting sample) during the second and third pre-enrolment screening visits. S1 Patients who had a LDL-C of 155 mg/dL (4.0 mmol/L) or higher at both screening visits with at least one measurement greater than or equal to 174 mg/dL (4.5 mmol/L) were included. Patients with LDL-C above 232 mg/dL (6.0 mmol/L) on both occasions were excluded. "Baseline lipid levels" were defined as the mean of the values measured at the second and third screening visits. There were no significant differences in lipid levels between the two screening measurements. S2 Fasting lipid levels were measured at 6month intervals during the trial follow-up.
Participants included in the study had no evidence of prior myocardial infarction (MI) based on medical history and baseline ECG, though individuals with stable angina not hospitalized within the previous 12 months were eligible in the original trial. S1 Pre-randomisation exclusion criteria established in the original trial included: S1 (1) history of treated MI with documented ECG or enzyme changes; (2) As reported previously, S1 the following endpoints are defined as follows:
Coronary heart disease (CHD) death and non-fatal myocardial infarction (MI):
1) Definite atherosclerotic CHD death: either or both of the following categories: a) Death certificate with consistent underlying or immediate cause plus one or more of the following: i) Preterminal hospitalisation with definite or suspect MI (see below). ii) Previous definite angina or suspect or definite MI when no cause other than atherosclerotic CHD could be ascribed as the cause of death. iii) Autopsy evidence of acute coronary arterial thrombosis and/or acute MI. b) Sudden and unexpected death (requires all 3 characteristics): i) Deaths occurring within 1 hour after the onset of severe symptoms or having last been seen without them. ii) No known non-atherosclerotic acute or chronic process or event that could have been potentially lethal. iii) An "unexpected" death occurs only in a person who is not confined to his home, hospital, or other institution because of illness within 24 hours before death.
2) Definite non-fatal MI: any one or more of the following categories using the stated definitions: i) Diagnostic ECG at the time of the event.
ii) Ischaemic cardiac pain and diagnostic enzymes. iii) Ischaemic cardiac pain with both equivocal enzymes and equivocal ECG. iv) An ECG at the annual visit or at an unscheduled visit is diagnostic for MI while the previous one was not.
3) Suspect atherosclerotic CHD death: one or both of the following categories: i) Death certificate with consistent underlying or immediate cause but neither adequate preterminal documentation of the event nor previous atherosclerotic CHD diagnosis. ii) Rapid and unexpected death (requires all 3 characteristics):
(1) Death occurring between one and 24 hours after the onset of severe symptoms or having last been seen without them. (2) No known non-atherosclerotic acute or chronic process or event that could have been potentially lethal. (3) An "unexpected death" occurs only in a person who is not confined to his home, hospital or other institution because of illness within 24 hours before death.
4)
Suspect MI: any one or more of the following categories using the stated definitions: i) Ischaemic cardiac pain, except when infarction is excluded by ECG or enzymes. ii) Diagnostic enzymes. iii) Equivocal ECG and equivocal enzymes. iv) Equivocal ECG alone, provided that it is not based on ST or T-wave changes only.
Cerebrovascular disease:
A single episode of motor paralysis, sensory or speech dysfunction, diplopia or visual disturbance lasting more than 1 hour, or repetitive episodes of a similar nature lasting for 5 min or more.
Extended long-term follow up
Following the final randomised trial visit pravastatin and placebo were withdrawn and patients returned to their primary care physicians. At 5 years after the completion of the randomised trial 38.7% and 35.2% of patients originally allocated to pravastatin and placebo arms, respectively, were taking statins (p<0.001) S4 . No later data on the proportion of individuals taking statin therapy were available for the subsequent years of follow-up. S4 At approximately 20 years since randomisation (15 years after the completion of the randomised trial) long-term mortality outcomes for the two original study groups (pravastatin and placebo) were compared, through linkage to electronic hospital discharge records held by the National Health Service for Scotland. S4,S5
Adverse events
Information on adverse events during the study have been described in detail in previous publications from WOSCOPS. S5-S8 Briefly, results at 5 years showed that the therapy with pravastatin, compared with placebo, did not unfavourably affect the liver function or produced myopathy; S6 pravastatin was found to protect from the development of diabetes S7 and from the risk of hospital admission due to cardiovascular causes without affecting non-cardiovascular hospitalizations; S8 finally, there was no evidence for an increased risk of incident fatal and non-fatal cancers, death from non-cardiovascular causes, or deaths from suicide or trauma with pravastatin. S6 Similarly, over the 20-year period of follow-up pravastatin did not adversely affect deaths (cardiovascular, noncardiovascular, cancer) and hospitalisations (cardiovascular, non-cardiovascular) rates. S5 Unfortunately, there are no post-trial data on non-serious adverse events.
2.-SUPPLEMENTAL TABLES
-eTable 1. Different definitions used in the literature for individuals with a primary elevation in LDL-C ≥190 mg/dL (≥4.91 mmol/L).
-eTable 2. Total Cholesterol, HDL-Cholesterol, Non-HDL-Cholesterol and Triglyceride levels during the randomised trial period stratified by LDL-cholesterol levels at baseline.
-eTable 4. Interaction tests of LDL-cholesterol and treatment for the different endpoints including LDLcholesterol as categorical (<190 and ≥190 mg/dL) or as a continuous measure for the on-trial and post-trial periods.
-eTable 8. Mortality endpoints during the randomised trial period in subjects with LDL-cholesterol ≥190 mg/dL allocated to pravastatin. □ LDL-C levels ≥190 mg/dL defined as FH phenotype. □ Alternative FH phenotype definitions including family history or maximally specific age-based LDL-C criteria decreased the FH phenotype prevalence but did not materially affect CHD risk estimates. Effect of therapy (vs. placebo) shown as hazard ratio (HR) and corresponding 95% confidence interval (95% CI) and p value. Note that MACE plus coronary revascularisation endpoint was used here instead of MACE alone in order to increase the number of events in each stratum and so the power of the analysis in an otherwise restricted sample to those with LDL-C ≥190 mg/dL allocated to pravastatin further stratified in different groups as shown in the table. (*) HRs are adjusted for age, history of hypertension, history of diabetes, smoking status, systolic and diastolic blood pressure, and body mass index. On-treatment LDL-C levels are defined as the mean of all LDL-C values measured after randomisation until the patient had an event or reached the end of the study. On-treatment LDL-C analyses excluded individuals with events in the first 6 months of the trial as first on-treatment LDL-C measurement was at 6 months after randomization. CHD: coronary heart disease. LDL-C: low-density lipoprotein cholesterol. MACE: major adverse cardiovascular events, defined as the composite of cardiovascular death, non-fatal myocardial infarction and non-fatal stroke. To convert values for cholesterol to mmol/L, multiply by 0.02586. eTable 7. CHD* and MACE* endpoints during the randomised trial period in subjects with LDL-cholesterol ≥190 mg/dL allocated to pravastatin. Effect of therapy (vs. placebo) shown as hazard ratio (HR) and corresponding 95% confidence interval (95% CI) and p value. Note that MACE plus coronary revascularisation endpoint was used here instead of MACE alone in order to increase the number of events in each stratum and so the power of the analysis in an otherwise restricted sample to those with LDL-C ≥190 mg/dL allocated to pravastatin further stratified in different groups as shown in the table. (*) Including coronary events (i.e. non-fatal MI and CHD death) as definite only. ( †) HRs are adjusted for age, history of hypertension, history of diabetes, smoking status, systolic and diastolic blood pressure, and body mass index. On-treatment LDL-C levels are defined as the mean of all LDL-C values measured after randomisation until the patient had an event or reached the end of the study. On-treatment LDL-C analyses excluded individuals with events in the first 6 months of the trial as first on-treatment LDL-C measurement was at 6 months after randomization. CHD: coronary heart disease. LDL-C: low-density lipoprotein cholesterol. MACE: major adverse cardiovascular events, defined as the composite of cardiovascular death, non-fatal MI and non-fatal stroke. MI: myocardial infarction. To convert values for cholesterol to mmol/L, multiply by 0.02586. eTable 8. Mortality endpoints during the randomised trial period in subjects with LDL-cholesterol ≥190 mg/dL allocated to pravastatin. ). Effect of therapy (vs. placebo) shown as hazard ratios (HR) and corresponding 95% confidence intervals (95% CI) and p value. 20year long-term follow-up: from randomisation to end of extended follow-up (on-trial plus post-trial periods). ASCVD: atherosclerotic cardiovascular disease. CHD: coronary heart disease. LDL-C: low-density lipoprotein cholesterol. MACE: major adverse cardiovascular events, defined as the composite of cardiovascular death, non-fatal myocardial infarction and non-fatal stroke. To convert values for cholesterol to mmol/L, multiply by 0.02586.
3.-SUPPLEMENTAL FIGURES
-eFigure 5. Major adverse cardiovascular events (including coronary events as definite-only) plus coronary revascularisation risk: Kaplan-Meier curves during the randomised trial period stratified by LDLcholesterol levels at baseline and treatment allocation. (To convert values for cholesterol to mmol/L, multiply by 0.02586)
eFigure 2. Low-density lipoprotein cholesterol levels during the randomised trial phase in participants without evidence of vascular disease at enrolment stratified by LDLcholesterol levels at baseline
Comparisons between pravastatin and placebo arms at year 1 and at end of trail in participants with LDL-C <190 mg/dL and in participants with LDL-C ≥190 mg/dL: all p<0.001. LDL-C: low-density lipoprotein cholesterol. To convert values for cholesterol to mmol/L, multiply by 0.02586. eFigure 3. Major adverse cardiovascular events plus coronary revascularisation risk: Kaplan-Meier curves during the randomised trial period stratified by primary severe hypercholesterolaemia status at baseline and treatment allocation.
5-year follow-up Kaplan-Meier analysis for major adverse cardiovascular disease events (MACE) plus coronary revascularisation endpoint, stratified by LDL-cholesterol levels at baseline (<190 or ≥190 mg/dL) and treatment allocation at randomisation (pravastatin or placebo). Number of events in each group were as follows: placebo, LDL-C <190 mg/dL: n=128; pravastatin, LDL-C <190 mg/dL: n=95; placebo, LDL-C ≥190 mg/dL: n=134; pravastatin, LDL-C ≥190 mg/dL: n=107. MACE: major adverse cardiovascular events, defined as the composite of cardiovascular death, non-fatal myocardial infarction and non-fatal stroke. CI: confidence interval. HR: hazard ratio. To convert values for cholesterol to mmol/L, multiply by 0.02586. eFigure 4. Coronary heart disease (definite-only coronary events) risk: Kaplan-Meier curves during the randomised trial period stratified by LDL-cholesterol levels at baseline and treatment allocation.
5-year follow-up Kaplan-Meier analysis for coronary heart disease (CHD) endpoint*, stratified by LDL-cholesterol levels at baseline (<190 or ≥190 mg/dL) and treatment allocation at randomisation (pravastatin or placebo). (*) Including coronary events (i.e. non-fatal MI and CHD death) as definite only. Number of events in each group were as follows: placebo, LDL-C <190 mg/dL: n=93; pravastatin, LDL-C <190 mg/dL: n=54; placebo, LDL-C ≥190 mg/dL: n=90; pravastatin, LDL-C ≥190 mg/dL: n=71. CI: confidence interval. HR: hazard ratio. To convert values for cholesterol to mmol/L, multiply by 0.02586.
